Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDP policy requirement for design verification data to be modified by FDA.

This article was originally published in The Gray Sheet

Executive Summary

SIMPLIFIED PDP OUTLINE UNDER CONSIDERATION BY FDA as a complement to its comprehensive policy on product development protocols. The agency says it would like to retain the existing policy because it would be helpful to manufacturers less familiar with the premarket review process, such as new start-ups. However, it also wants to address complaints from some manufacturers that the comprehensive policy is too detailed and prescriptive, and to this end may develop a simplified format.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel